Azacitidine for Secondary MDS and as a Bridging Option for Patients with MDS/CMML Before Allogeneic Transplant


Azacitidine for Secondary MDS and as a Bridging Option for Patients with MDS/CMML Before Allogeneic Transplant
Slides from presentations at ASH 2010 and transcribed comments from a recent interview with B Douglas Smith, MD (1/4/11)
Sekeres MA et al. Therapeutic response to azacitidine (AZA) in patients with secondary myelodysplastic syndromes (sMDS) enrolled in the AVIDA registry. Proc ASH 2010;Abstract 2931.

Field T et al. Prospective trial of pre-transplant 5-azacitidine on hematopoietic cell transplantation outcomes for myelodysplastic syndrome and CMML. Proc ASH 2010;Abstract 1333.

Dr Smith is Associate Professor of Oncology at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland.